

Press release from Emotra AB (publ)

Göteborg, May 26, 2017

EMOTRA AB: Resolution on a new share issue with right of priority for the market launch of EDOR®

Today, May 26, 2017, EMOTRA AB (“Emotra”) announced that its Board of Directors have decided on a new share issue with right of priority. This new share issue will comprise a maximum of 5,287,700 shares and the public has been invited to participate. If fully subscribed, this new share issue will provide Emotra with a cash injection of appr. 17.5 MSEK before issuing costs. The Company has already received written commitments for approximately 3 MSEK, or about 17 percent of the issue amount. This new share issue was decided with reference to a resolution passed at the extraordinary shareholder meeting held on May 19, 2017. The resolution granted the Board the authority to carry out a new share issue with right of priority in order to raise more working capital to finance the market launch of the Company’s EDOR® method.

Comments from Claes Holmberg, Emotra’s CEO

“Emotra has closed EUDOR-A, a large, clinical multi-centre study which involved more than 1,500 patients at 16 leading psychiatric clinics in nine European countries, to examine the method’s efficacy, reliability and how it can best be utilised in clinical practice. In March, 2017, EUDOR-A was closed, on budget and on schedule, and with very satisfying results—a tenfold reduction in the suicide rate in the patient group that was tested using EDOR® and in which the test results were used as a basis for decisions to initiate suicide-preventive measures. We now see strong opportunities to commercialise EDOR®, especially since a number of clinical studies, most recently EUDOR-A, have provided clinical proof that hyporeactive individuals are extra vulnerable to suicide attempts, and because the method is an objective and reliable way to determine whether a person is hyporeactive. In our opinion, EDOR® is a mature product that has proven itself amply in clinical practice and, therefore, the time is ripe for a commercial launch of the method. In order to reap the full market potential and commercial opportunities of the EDOR® method, we plan on raising a maximum of 17.5 MSEK through a new share issue with right of priority. This new capital will allow us to carry out our market launch of the method. We plan on initiating our EDOR® marketing activities in Q2/Q3 of 2017, with the goal of achieving a broad market acceptance among leading psychiatric clinics in the western hemisphere within two years.”

New share issue with right of priority in anticipation of the commercial introduction of EDOR®

Emotra plans on issuing new shares to raise a total of appr. 17.5 MSEK. Emotra’s primary goal with the capital that this new share issue with right of priority will provide is to finance the Company’s planned market launch of EDOR® following the promising results of our clinical multi-centre study, EUDOR-A. The funds will primarily be used to establish a marketing organisation within the Company with the goal of making EDOR® commercially available. Emotra also intends to dedicate some of the funds to continued product development of both our hardware and our software, as well as to continued research in order to secure the Company’s position at the forefront of this area.

The offering in summary

- **Subscription period:** June 7 – 21, 2017
- **Subscription price:** SEK 3.30 per share
- **Record day:** June 2, 2017. The final day for trading in the company’s shares including the right to obtain subscription rights is May 31, 2017, and the first day without subscription rights is June 1, 2017.
- **Right of priority:** Shareholders whose Emotra shares are registered on June 2, 2017 will have right of priority in the new share issue. Each outstanding share entitles the owner to one (1) subscription right. Nine (9) subscription rights allow the shareholder to subscribe to five (5) new shares. Please note that this new share issue is also open to the general public.
- **Issue volume:** The offering comprises a maximum of 5,287,700 new shares. If fully subscribed, this new share issue will provide the Company with a cash injection of 17,449,410 SEK before issue expenses.
- **Number of shares outstanding before the new issue:** 9,517,860.
- **Value (pre-money):** Approximately 31.4 MSEK.

- **Trading in subscription rights:** Trading in subscription rights will be carried out on AktieTorget from June 7 to June 19, 2017.
- **Trading in PSS:** Trading in PSS (Paid Subscribed Shares) will be carried out on AktieTorget from June 7, 2017, until the share issue has been registered at Bolagsverket (The Swedish Companies Registration Office). We expect this registration to be completed in the middle of July 2017.
- **Subscription commitments:** Emotra has received subscription commitments for a total of 3 MSEK, which equals approximately 17% of the total issue value.
- **Market place:** Emotra's share is listed on AktieTorget.
- **ISIN code:** SE0006851507

Memorandum (including complete terms and instructions and further information about subscription commitments) as well as a teaser and subscription form without right of priority will be available on the company's web site (www.emotra.se), Sedermera Fondkommission's web site (www.sedermera.se) and AktieTorget's web site (www.aktietorget.se) no later than the commencement of the subscription period.

Financial Advisor

Emotra's Financial Advisor in connection with the planned rights issue is Sedermera Fondkommission.

For further information about the planned rights issue, please contact:

Sedermera Fondkommission
Telephone: +46 40 615 14 10
E-mail: info@sedermera.se

For further information about Emotra, please contact:

Claes Holmberg, CEO
Telephone: + 46 708 25 45 47
E-mail: claes@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on May 26, 2017 under the above contact's supervision.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR[®], is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se